INTERNATIONAL STANDARD

ISO 10993-13

Second edition 2010-06-15

Biological evaluation of medical devices —

Part 13:

Identification and quantification of degradation products from polymeric medical devices

Évaluation biologique des dispositifs médicaux —

Partie 13: Identification et quantification de produits de dégradation de dispositifs médicaux à base de polymères

ISO 10993-13:2010

https://standards.iteh.ai/catalog/standards/iso/b65c8f15-b480-4d46-bc11-ffb1c6e383c5/iso-10993-13-2010



PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.

iTeh Standards (https://standards.iteh.ai) Document Preview

ISO 10993-13:2010

https://standards.iteh.ai/catalog/standards/iso/b65c8f15-b480-4d46-bc11-ffb1c6e383c5/iso-10993-13-2010



COPYRIGHT PROTECTED DOCUMENT

© ISO 2010

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents Page Forewordiv Introduction.......vi 1 Scope......1 2 3 4.1 4.2 Accelerated degradation test5 4.3 5 Test procedures......6 5.1 General6 Initial material characterization......6 5.2 5.4 Real-time degradation test in a simulated environment9 Test report ______10 Annex A (informative) Analytical methods.......11

ISO 10993-13:2010

https://standards.iteh.ai/catalog/standards/iso/b65c8f15-b480-4d46-bc11-ffb1c6e383c5/iso-10993-13-2010

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 10993-13 was prepared by Technical Committee ISO/TC 194, Biological evaluation of medical devices.

This second edition cancels and replaces the first edition (ISO 10993-13:1998), which has been technically revised.

ISO 10993 consists of the following parts, under the general title *Biological evaluation of medical devices*:

- Part 1: Evaluation and testing within a risk management process
- Part 2: Animal welfare requirements

ISO 10993-13:2010

- | Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity | 11-ffb | c6e383c5/iso-10993-13-2010
- Part 4: Selection of tests for interactions with blood
- Part 5: Tests for in vitro cytotoxicity
- Part 6: Tests for local effects after implantation
- Part 7: Ethylene oxide sterilization residuals
- Part 9: Framework for identification and quantification of potential degradation products
- Part 10: Tests for irritation and skin sensitization
- Part 11: Tests for systemic toxicity
- Part 12: Sample preparation and reference materials
- Part 13: Identification and quantification of degradation products from polymeric medical devices
- Part 14: Identification and quantification of degradation products from ceramics
- Part 15: Identification and quantification of degradation products from metals and alloys

- Part 16: Toxicokinetic study design for degradation products and leachables
- Part 17: Establishment of allowable limits for leachable substances
- Part 18: Chemical characterization of materials
- Part 19: Physico-chemical, morphological and topographical characterization of materials [Technical specification]
- Part 20: Principles and methods for immunotoxicology testing of medical devices [Technical specification]

iTeh Standards (https://standards.iteh.ai) Document Preview

ISO 10993-13:2010

https://standards.iteh.ai/catalog/standards/iso/b65c8f15-b480-4d46-bc11-ffb1c6e383c5/iso-10993-13-2010

© ISO 2010 - All rights reserved

Introduction

Degradation products covered by this part of ISO 10993 are formed primarily by chemical bond scission due to hydrolytic and/or oxidative processes in an aqueous environment such as the human body. It is recognised that additional biological factors, such as enzymes, other proteins and cellular activity, can alter the rate and nature of degradation.

It should be kept in mind that a polymeric device can contain residuals and leachables such as monomers, oligomers, solvents, catalysts, additives, fillers and processing aids. These components which, if present, can interfere with the identification and quantification of the degradation products need to be considered and accounted for. It should be recognised that residual monomers can generate the same degradation products as the polymer itself. If the reader is solely interested in using the results from a degradation test as input to further biological evaluation tests, the reader might not be interested in distinguishing between a leachable and a degradation product. If this is the case, then the care taken to separate the leachable from the degradation product may not be needed.

Because of the generalized nature of this part of ISO 10993, product standards, when available, that address degradation product formation under more relevant conditions of use, may be considered as an alternative. This part of ISO 10993 is suitable for screening new polymeric materials and/or modified polymeric materials with unknown degradation behaviour in body contact. This part of ISO 10993 does not reproduce degradation *in vivo*. The user of this part of ISO 10993 can consider running additional degradation tests addressing *in vivo* degradation issues.

Long-term implants might not degrade within the time frame of the tests shown in this part of ISO 10993. The intention of this part of ISO 10993 is to help determine the biological hazards from potential degradation products from polymer components of medical devices. As noted above, those products might come from a variety of degradation mechanisms. This part of ISO 10993 is not intended to be a complete analysis of the degradation of the medical device and the impact on its performance. The interested user is referred to the relevant product standards.

The identified and quantified degradation products form the basis for biological evaluation in accordance with ISO 10993-1, for risk assessment in accordance with ISO 10993-17 and, if appropriate, for toxicokinetic studies in accordance with ISO 10993-16.

Biological evaluation of medical devices —

Part 13:

Identification and quantification of degradation products from polymeric medical devices

1 Scope

This part of ISO 10993 provides general requirements for the design of tests in a simulated environment for identifying and quantifying degradation products from finished polymeric medical devices ready for clinical use.

This part of ISO 10993 describes two test methods to generate degradation products, an accelerated degradation test as a screening method and a real-time degradation test in a simulated environment. For materials that are intended to polymerize *in situ*, the set or cured polymer is used for testing. The data generated are used in the biological evaluation of the polymer. This part of ISO 10993 considers only non-resorbable polymers. Similar but appropriately modified procedures may be applicable for resorbable polymers.

This part of ISO 10993 considers only those degradation products generated by a chemical alteration of the finished polymeric device. It is not applicable to degradation of the device induced during its intended use by mechanical stress, wear or electromagnetic radiation or biological factors such as enzymes, other proteins and cellular activity.

NOTE An informative text discussing environmental stress cracking (ESC) of polymers is included as a potential aid to the design of degradation studies (see Annex B).

The biological activity of the debris and soluble degradation products is not addressed in this part of ISO 10993, but should be evaluated according to the principles of ISO 10993-1, ISO 10993-16 and ISO 10993-17.

Because of the wide range of polymeric materials used in medical devices, no specific analytical techniques are identified or given preference. No specific requirements for acceptable levels of degradation products are provided in this part of ISO 10993.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 3696, Water for analytical laboratory use — Specification and test methods

ISO 10993-1, Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process

ISO 10993-9, Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products

ISO 10993-12, Biological evaluation of medical devices — Part 12: Sample preparation and reference materials

ISO 10993-17, Biological evaluation of medical devices — Part 17: Establishment of allowable limits for leachable substances

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1

residual monomer

unreacted chemical compound(s) used to build the polymeric chains, which is still present in the final polymeric material

3.2

degradation product

chemical compound derived from the breakdown of the polymeric material, including any compound produced by consecutive chemical reactions

3.3

polymeric material

materials consisting of long-chain and/or crosslinked molecules composed of units called monomers

3.4

hydrolytic degradation

scission of chemical bonds in a polymer by the attack of water

NOTE The water can have a neutral, acidic or alkaline pH value and can contain additional chemical compounds or ions.

3.5

oxidative degradation

scission of chemical bonds in a polymer by the attack of one or more oxidizing agents

3.6

debri

particulate material produced by the degradation of a polymeric material

4 Degradation test methods

4.1 General procedures

4.1.1 Test design

In accordance with ISO 10993-9, degradation tests shall be used to generate, identify and/or quantify degradation products. If degradation is observed in an accelerated test, identification and quantification of the degradation products can provide sufficient information for risk analysis. If identification and quantification of degradation products from the accelerated test do not provide sufficient information for the risk analysis, real-time testing shall be performed. The sequence of steps that shall be followed is described in detail in this part of ISO 10993.

NOTE The accelerated degradation test can be used as a screening test. If no degradation is observed in the accelerated test, no real-time degradation test should be necessary.

4.1.2 Sample preparation

When not specifically addressed by the selected method(s), the general aspects of sample preparation shall be in accordance with ISO 10993-12.

4.1.3 Initial material characterization

The analytical methods used for the initial material characterization shall be appropriate for the polymeric material under investigation. The analytical techniques used shall be reported and justified.

Annex A presents a list of analytical methods and their application range for the characterization of polymeric materials.

4.1.4 Test solutions and apparatus

4.1.4.1 Test solutions

4.1.4.1.1 General

All test solution(s) used shall be described and justified in the test report.

The test solution shall be selected to be as similar as possible to the intended environment in which the polymeric medical device is going to be used.

If the service environment cannot be simulated, test solutions given in 4.1.4.1.2 and 4.1.4.1.3 can be used as a first screening for degradation. These test solutions can be more challenging or less challenging to the polymeric material with respect to the intended degradation mechanisms than the *in vivo* environment.

Other test solutions for a specific polymer or a specific service environment may be chosen.

NOTE If a biological assay of the debris or the degradation solution is to be made, then the use of antibacterial or antifungal additives will interfere with these assays and it might be necessary to maintain a sterile environment for the duration of the real-time degradation test.

4.1.4.1.2 Test solutions for hydrolytic degradation

For hydrolytic degradation, the following solutions are suggested:

- a) water for analytical laboratory use, grade 2, in accordance with ISO 3696; 38365/66-10993-13-2010
- b) buffer.

NOTE See ISO 13781 for examples of buffers used in hydrolytic degradation studies.

4.1.4.1.3 Test solutions for oxidative degradation

For oxidative degradation, the following solutions are suggested:

- a) water and hydrogen peroxide, e.g. 3 % hydrogen peroxide solution, Pharmacopoeia grade;
- b) Fenton's reagent [mixture of dilute hydrogen peroxide solution and iron(II) salts, e.g. 100 μ mol Fe²⁺ and 1 mmol H₂O₂].

These oxidative solutions might not be stable at elevated temperatures or for a prolonged time. Therefore, the oxidative capacity shall be maintained in an appropriate range.

This stability range shall be specified, justified and reported.

4.1.4.2 Container

Depending on the test solution, chemical grade glassware, polytetrafluoroethylene or polypropylene containers in an enclosed system shall be used. Controls shall be used in order to assess contaminants from the container. Evidence shall be provided that containers do not interfere with the analysis.

© ISO 2010 – All rights reserved

4.1.4.3 Balance

The balance used to determine mass loss shall be capable of weighing the initial sample mass with the precision required. For materials designed to be resorbed, a precision of 1 % is appropriate, for materials designed to resist degradation, a precision of at least 0,1 % shall be used. The precision of the balance for the final sample mass in the case of resorbable polymers shall be 0,1 %, and in the case of stable polymers 0,01 %, of the total sample mass.

The precision and standard deviation of the method used for determining mass loss shall be stated in the test report.

4.1.4.4 Drying apparatus

Any apparatus capable of drying the test samples to constant mass without contamination or loss of volatile degradation products shall be used.

The apparatus shall be described and defined in the test report.

4.1.4.5 Vacuum source

Any apparatus capable of producing a sufficient vacuum (< 0,5 kPa) in the drying apparatus is appropriate.

The apparatus shall be described and defined in the test report.

4.1.4.6 Separation apparatus

Any apparatus capable of separating the debris produced during the degradation study may be used. This can involve an inert filter, a temperature-controlled centrifuge or a combination thereof.

The apparatus shall be described and defined in the test report.

4.1.5 Number of test samples

At least three test samples shall be used for each test period. These should be the finished product itself or representative samples thereof. A separate container shall be used for each sample. One blank shall be used for each test period.

If a valid statistical analysis is required, more samples at each test period should be used, as appropriate.

4.1.6 Shape and size of test samples

The size and the shape of the specimen are critical for the generation of relevant amounts of degradation products. If a part of the finished device is used as the test sample, then surfaces which are normally not in contact with the biological environment should be avoided or minimized.

The size, shape and surface area of the sample should be chosen in such a way that equilibrium with the degradation solution and a constant mass for the determination of the mass balance can be reached in an acceptable time.

If the medical device consists of more than one material, combination effects should be taken into consideration. It is recommended that representative parts of the other materials of the device, not intended to be tested by this part of ISO 10993, should be added to the test solution.

NOTE 1 Under certain circumstances, it might be necessary to fabricate a test sample using the same processing, cleaning and sterilization methods as are used in the fabrication of the device.

NOTE 2 With resorbable polymers, equilibrium with the degradation solution might not be reached.